NEW DELHI: India's leading drug regulatory body, the Drugs Controller General of India's Subject Expert Committee has given Biological E's Covid vaccine Corbevax restricted emergency use authorization for adolescents aged 12 to 18.
According to a source acquainted with the situation, the approval is subject to certain conditions.This approval for Corbevax is anticipated to hasten the ongoing vaccination campaign for youngsters aged 15 to 18 years old, as well as those aged 12 to 14.
Two vaccinations for minors have already been approved by the DCGI: Bharat Biotech's Covaxin and Ahmedabad-based Zydus Cadilla's ZyCovD vaccine. The ZyCovD vaccine is the first plasmid-DNA vaccination to be authorised for children over the age of 12.
Corbevax is India's first RBD protein sub-unit vaccine against Covid-19, and it is based on a protein antigen technology that binds to the ACE2 receptor on the host cell membrane and aids virus entry. The immune system of the body is stimulated to make antibodies to protect against infection by the body's own cells.
Oxford Study finds weight loss shortens risk of colorectal cancer
